Quality control for fabrication of biolised cardiac prostheses

The clinical application of cardiac prostheses requires a pump that has the highest reliability and no defects. Considering the possibility of clinical implantation in the future, quality control and inspection systems have been incorporated into the fabrication process of biolised cardiac prostheses. Inspection procedures are employed at every strategic point in the pump fabrication process, including visual inspection, dimensional check, material test, performance test and s.e.m. observation. Over the past one-and-a-half years we have inspected 480 components and assemblies from 49 total artificial hearts and left-ventricular assist devices. A total of 93 defects and failures were detected by the inspection system, of which 48 defects were repaired in the fabrication lines. The remaining components were rejected and removed from the pump fabrication lines. The quality of trileaflet dura mater valves was significantly improved by the incorporation of the quality-control system. Since most of the fabrication and assembly are performed manually at the present time, the quality control has contributed greatly to improved device reliability.

[1]  K. V. van Kampen,et al.  Artificial heart with hemispherical ventricles II and disseminated intravascular coagulation. , 1971, Transactions - American Society for Artificial Internal Organs.

[2]  J. Lawson,et al.  A comparsion of polyurethane and silastic artificial hearts in 10 long survival experiments in calves. , 1975, Transactions - American Society for Artificial Internal Organs.

[3]  Y Nosé,et al.  Human thoracic anatomy relevant to implantable artificial hearts. , 1978, Artificial organs.

[4]  D Hillegass,et al.  HIGH FLEX RUBBER FOR BLOOD PUMP DIAPHRAGMS , 1977, Transactions - American Society for Artificial Internal Organs.

[5]  H. Kambic,et al.  A simple in vitro screening test for blood compatibility of materials. , 1976, Journal of biomedical materials research.

[6]  I. Koshino,et al.  Survival for 145 days with a total artificial heart. , 1977, Journal of Thoracic and Cardiovascular Surgery.

[7]  I. Koshino,et al.  Application of aldehyde treatments to cardiovascular devices. , 1976, Transactions - American Society for Artificial Internal Organs.

[8]  Y Nosé,et al.  Artificial heart constructed with biological material. , 1971, Transactions - American Society for Artificial Internal Organs.

[9]  Y. Nosé,et al.  Biolized intrathoracic left ventricular assist device (LVAD). , 1977, Medical instrumentation.

[10]  F. Iwaya,et al.  Comparison of pneumatic and electrically powered total artificial hearts in vivo. , 1978, Transactions - American Society for Artificial Internal Organs.

[11]  Y. Nosé,et al.  Natural tissue as a biomaterial. , 1974, Biomaterials, medical devices, and artificial organs.

[12]  Y. Nosé,et al.  Dura mater value for cardiac prosthesis. , 1975, Transactions - American Society for Artificial Internal Organs.

[13]  D. Olsen,et al.  PULMONARY HEPATIC AND RENAL PATHOLOGY ASSOCIATED WITH AN ARTIFICIAL HEART , 1973, Transactions - American Society for Artificial Internal Organs.